A randomized, open label, single center, phase I, two way, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new granule formulation with the reference dispersible formulation in healthy subjects.
Latest Information Update: 11 Mar 2016
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload; Myelodysplastic syndromes
- Focus Pharmacokinetics
- Sponsors Novartis
Most Recent Events
- 11 Mar 2016 New trial record